PAREXEL is Acquired by Pamplona Capital Management

June 22, 2017

Applied Clinical Trials

PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.

Read the full release here.

Related Content:

News